ArticleJournal of ovarian research2026
Repurposing trifluoperazine as a potential therapeutic agent for ovarian cancer: mechanistic insight via SRC/PI3K/AKT signaling pathway inhibition.
Article in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveThis study evaluates the efficacy of trifluoperazine in treating ovarian cancer and investigates its potential molecular mechanisms through in vitro and in vivo experiments, as well as network pharmacology analysis.
methodsWe used the CCK-8 assay to assess cell proliferation in five ovarian cancer cell lines (ES-2, SK-OV-3, OVCAR-3, OV-90, ID8). We performed scratch and Transwell assays on SK-OV-3 and ID8 cells to evaluate their migration and invasion capabilities. Apoptosis, proliferation, and reactive oxygen species (ROS) levels in ID8 cells were measured using Acridine Orange/Propidium Iodide (AO/PI) staining, EdU assays, and ROS assays, respectively. A xenograft mouse model was employed to assess the effect of trifluoperazine on tumor growth. Network pharmacology was used to identify common targets between trifluoperazine and ovarian cancer, followed by Western blot (WB) experiments to validate the protein expression levels of the SRC/PI3K/Akt signaling pathway.
resultsTrifluoperazine inhibited cell growth in a dose-dependent manner, with ES-2 cells showing the greatest sensitivity. Migration, invasion, and proliferation of SK-OV-3 and ID8 cells were significantly reduced, while apoptosis and ROS levels were increased. In vivo, trifluoperazine inhibited tumor growth, with only a slight decrease in body weight observed. Network pharmacology identified 110 common targets, with the main targets enriched in the PI3K-Akt pathway. WB analysis confirmed the downregulation of SRC, PI3K, and Akt proteins in cells treated with trifluoperazine.
conclusionTrifluoperazine inhibits ovarian cancer progression in vitro and in vivo by targeting the SRC/PI3K/Akt signaling pathway, providing a potential new therapeutic strategy for ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.